1. |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
|
2. |
Ren F, Fei Q, Qiu K, et al. Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation. J Exp Clin Cancer Res, 2024, 43(1): 96.
|
3. |
Concepcion CP, Ma S, LaFave LM, et al. Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung. Cancer Discov, 2022, 12(2): 562-585.
|
4. |
Liang X, Gao X, Wang F, et al. Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer. Cancer Med, 2023, 12(13): 14171-14182.
|
5. |
Tian Y, Xu L, Li X, et al. SMARCA4: current status and future perspectives in non-small-cell lung cancer. Cancer Lett, 2023, 554: 216022.
|
6. |
Jiang J, Chen Z, Gong J, et al. Thoracic SMARCA4-deficient undifferentiated tumor. Discov Oncol, 2023, 14(1): 51.
|
7. |
Armon S, Hofman P, Ilié M. Perspectives and issues in the assessment of SMARCA4 deficiency in the management of lung cancer patients. Cells, 2021, 10(8): 1920.
|
8. |
Swanson K, Wu E, Zhang A, et al. From patterns to patients: advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. Cell, 2023, 186(8): 1772-1791.
|
9. |
Li Y, Wang J, Wang F, et al. Identification of specific cell subpopulations and marker genes in ovarian cancer using single-cell RNA sequencing. Biomed Res Int, 2021, 2021: 1005793.
|
10. |
Liang L, Yu J, Li J, et al. Integration of scRNA-Seq and bulk RNA-Seq to analyse the heterogeneity of ovarian cancer immune cells and establish a molecular risk model. Front Oncol, 2021, 11: 711020.
|
11. |
De Zuani M, Xue H, Park JS, et al. Single-cell and spatial transcriptomics analysis of non-small cell lung cancer. Nat Commun, 2024, 15(1): 4388.
|
12. |
Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics, 2008, 9: 559.
|
13. |
Xu Z, Song J, Cao L, et al. Improving ovarian cancer treatment decision using a novel risk predictive tool. Aging (Albany NY), 2022, 14(8): 3464-3483.
|
14. |
Wu Y, Luo J, Li H, et al. B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma. Ann Transl Med, 2022, 10(6): 295.
|
15. |
Qiu BQ, Lin XH, Lai SQ, et al. ITGB1-DT/ARNTL2 axis may be a novel biomarker in lung adenocarcinoma: a bioinformatics analysis and experimental validation. Cancer Cell Int, 2021, 21(1): 665.
|
16. |
Song C, Wu Z, Wang Q, et al. A combined two-mRNA signature associated with PD-L1 and tumor mutational burden for prognosis of lung adenocarcinoma. Front Cell Dev Biol, 2021, 9: 634697.
|
17. |
Xue T, Chen Y, Xu J, et al. Cyclovirobuxine D inhibits growth and progression of non-small cell lung cancer cells by suppressing the KIF11-CDC25C-CDK1-CyclinB1 G2/M phase transition regulatory network and the NFκB/JNK signaling pathway. Int J Oncol, 2023, 62(5): 57.
|
18. |
Dagogo-Jack I, Schrock AB, Kem M, et al. Clinicopathologic characteristics of BRG1-deficient NSCLC. J Thorac Oncol, 2020, 15(5): 766-776.
|
19. |
DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol, 2019, 19(6): 369-382.
|
20. |
Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity, 2013, 39(4): 782-795.
|
21. |
Lv M, Tang D, Yu H, et al. Novel FSIP2 variants induce super-length mitochondrial sheath and asthenoteratozoospermia in humans. Int J Biol Sci, 2023, 19(2): 393-411.
|
22. |
Ying H, Lin A, Liang J, et al. Association between FSIP2 mutation and an improved efficacy of immune checkpoint inhibitors in patients with skin cutaneous melanoma. Front Mol Biosci, 2021, 8: 629330.
|
23. |
Yan Z, Zhong Z, Shi C, et al. The prognostic marker KRT81 is involved in suppressing CD8+ T cells and predicts immunotherapy response for triple-negative breast cancer. Cancer Biol Ther, 2024, 25(1): 2355705.
|
24. |
Gao M, Wang M, Zhou S, et al. Machine learning-based prognostic model of lactylation-related genes for predicting prognosis and immune infiltration in patients with lung adenocarcinoma. Cancer Cell Int, 2024, 24(1): 400.
|
25. |
Jin ML, Gong Y, Ji P, et al. In vivo CRISPR screens identify RhoV as a pro-metastasis factor of triple-negative breast cancer. Cancer Sci, 2023, 114(6): 2375-2385.
|
26. |
You J, Yu Q, Chen R, et al. A prognostic model for lung adenocarcinoma based on cuproptosis and disulfidptosis related genes revealing the key prognostic role of FURIN. Sci Rep, 2025, 15(1): 6057.
|
27. |
Sumaiya K, Langford D, Natarajaseenivasan K, et al. Macrophage migration inhibitory factor (MIF): a multifaceted cytokine regulated by genetic and physiological strategies. Pharmacol Ther, 2022, 233: 108024.
|
28. |
Fey RM, Nichols RA, Tran TT, et al. MIF and CD74 as emerging biomarkers for immune checkpoint blockade therapy. Cancers (Basel), 2024, 16(9): 1773.
|
29. |
Zeng L, Hu P, Zhang Y, et al. Macrophage migration inhibitor factor (MIF): potential role in cognitive impairment disorders. Cytokine Growth Factor Rev, 2024, 77: 67-75.
|
30. |
Zhang L, Woltering I, Holzner M, et al. CD74 is a functional MIF receptor on activated CD4+ T cells. Cell Mol Life Sci, 2024, 81(1): 296.
|
31. |
Zhang L, Xiong Z, Chen Z, et al. Periplakin attenuates liver fibrosis via reprogramming CD44Low cells into CD44High liver progenitor cells. Cell Mol Gastroenterol Hepatol, 2025, 19(7): 101498.
|
32. |
Yang Y, Li J, Lei W, et al. CXCL12-CXCR4/CXCR7 axis in cancer: from mechanisms to clinical applications. Int J Biol Sci, 2023, 19(11): 3341-3359.
|
33. |
Hassn Mesrati M, Syafruddin SE, Mohtar MA, et al. CD44: a multifunctional mediator of cancer progression. Biomolecules, 2021, 11(12): 1850.
|